Adolescents, Crohn Disease, Inflammatory Bowel Diseases, Ulcerative Colitis, Yoga
Conditions
Keywords
inflammatory bowel disease, adolescent, yoga, mind-body
Brief summary
An 8-week yoga intervention to determine the feasibility and acceptability of yoga as a supplemental therapy in the management of inflammatory bowel disease in the adolescent population.
Detailed description
Youth with IBD experience abdominal pain, diarrhea, weight loss, and psychological suffering related to their disease process. While many biologic and non-biologic therapies are available to target the inflammatory component of IBD, youth with IBD could benefit from a more holistic therapy that addresses psychological wellness, which has been shown, in turn, to reduce disease burden. It is known that stress (multiple varieties) leads to IBD flares. It is also known that mind-body intervention reduces stress. The mind-gut connection is widely discussed in medical circles, however, current therapies have not capitalized on it. The investigators would like to know if an easily accessible mind-body intervention (yoga) can improve wellness, lower stress levels, and reduce intestinal inflammation in youth with IBD. The study will be an 8-week feasibility pilot. Participants will be asked to participate in online yoga videos and in-studio yoga sessions. Participants will be asked to complete multiple surveys throughout the intervention and continue receiving standard care from their primary gastroenterology team.
Interventions
BEHAVIORALYoga
Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
Sponsors
Stanford University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Age 10-21 * Diagnosis of Crohn's Disease or Ulcerative Colitis * Patient of a Stanford Children's Health or Stanford-affiliated Pediatric Gastroenterologist * Ability to attend in-person meetings/training
Exclusion criteria
* Initiation of biologic therapy in prior 3 months * Hospital admission in prior 2 months * Major surgery in prior 1 month * PUCAI/PCDAI \>65 * Current pregnancy * Severe developmental or intellectual disability * Non-english speaking * Not participating in another concurrent clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of acceptability | 1 hour focus group at conclusion of intervention. | Focus Group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fecal Calprotectin | 6 weeks (Prior to intervention; After conclusion of intervention) | Stool biomarker that indicates intestinal inflammation |
| Pediatric Ulcerative Colitis Activity Index | 6 weeks (Prior to intervention; After conclusion of intervention) | 5 question assessment tool for disease tracking for patient's with ulcerative colitis |
| PROMIS-37 | 6 weeks (Prior to intervention; After conclusion of intervention) | NIH Pediatric Assessment Tool |
Countries
United States
Outcome results
None listed